StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the stock.

DBVT has been the topic of a number of other reports. JMP Securities reiterated a “market outperform” rating and issued a $25.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright lifted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBVT opened at $3.33 on Friday. The firm has a market cap of $68.50 million, a P/E ratio of -0.77 and a beta of 0.64. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.70. The company has a 50 day simple moving average of $3.46 and a two-hundred day simple moving average of $4.06.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.